Cargando…

HDL cholesterol: reappraisal of its clinical relevance

BACKGROUND: While several lines of evidence prove that elevated concentrations of low-density lipoproteins (LDL) causally contribute to the development of atherosclerosis and its clinical consequences, high-density lipoproteins are still widely believed to exert atheroprotective effects. Hence, HDL...

Descripción completa

Detalles Bibliográficos
Autores principales: März, Winfried, Kleber, Marcus E., Scharnagl, Hubert, Speer, Timotheus, Zewinger, Stephen, Ritsch, Andreas, Parhofer, Klaus G., von Eckardstein, Arnold, Landmesser, Ulf, Laufs, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565659/
https://www.ncbi.nlm.nih.gov/pubmed/28342064
http://dx.doi.org/10.1007/s00392-017-1106-1
_version_ 1783258425259458560
author März, Winfried
Kleber, Marcus E.
Scharnagl, Hubert
Speer, Timotheus
Zewinger, Stephen
Ritsch, Andreas
Parhofer, Klaus G.
von Eckardstein, Arnold
Landmesser, Ulf
Laufs, Ulrich
author_facet März, Winfried
Kleber, Marcus E.
Scharnagl, Hubert
Speer, Timotheus
Zewinger, Stephen
Ritsch, Andreas
Parhofer, Klaus G.
von Eckardstein, Arnold
Landmesser, Ulf
Laufs, Ulrich
author_sort März, Winfried
collection PubMed
description BACKGROUND: While several lines of evidence prove that elevated concentrations of low-density lipoproteins (LDL) causally contribute to the development of atherosclerosis and its clinical consequences, high-density lipoproteins are still widely believed to exert atheroprotective effects. Hence, HDL cholesterol (HDL-C) is in general still considered as “good cholesterol”. Recent research, however, suggests that this might not always be the case and that a fundamental reassessment of the clinical significance of HDL-C is warranted. METHOD: This review article is based on a selective literature review. RESULTS: In individuals without a history of cardiovascular events, low concentrations of HDL-C are inversely associated with the risk of future cardiovascular events. This relationship may, however, not apply to patients with metabolic disorders or manifest cardiovascular disease. The classical function of HDL is to mobilise cholesterol from extrahepatic tissues for delivery to the liver for excretion. These roles in cholesterol metabolism as well as many other biological functions of HDL particles are dependent on the number as well as protein and lipid composition of HDL particles. They are poorly reflected by the HDL-C concentration. HDL can even exert negative vascular effects, if its composition is pathologically altered. High serum HDL-C is therefore no longer regarded protective. In line with this, recent pharmacological approaches to raise HDL-C concentration have not been able to show reductions of cardiovascular outcomes. CONCLUSION: In contrast to LDL cholesterol (LDL-C), HDL-C correlates with cardiovascular risk only in healthy individuals. The calculation of the ratio of LDL-C to HDL-C is not useful for all patients. Low HDL-C should prompt examination of additional metabolic and inflammatory pathologies. An increase in HDL-C through lifestyle change (smoking cessation, physical exercise) has positive effects and is recommended. However, HDL-C is currently not a valid target for drug therapy.
format Online
Article
Text
id pubmed-5565659
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55656592017-09-06 HDL cholesterol: reappraisal of its clinical relevance März, Winfried Kleber, Marcus E. Scharnagl, Hubert Speer, Timotheus Zewinger, Stephen Ritsch, Andreas Parhofer, Klaus G. von Eckardstein, Arnold Landmesser, Ulf Laufs, Ulrich Clin Res Cardiol Review BACKGROUND: While several lines of evidence prove that elevated concentrations of low-density lipoproteins (LDL) causally contribute to the development of atherosclerosis and its clinical consequences, high-density lipoproteins are still widely believed to exert atheroprotective effects. Hence, HDL cholesterol (HDL-C) is in general still considered as “good cholesterol”. Recent research, however, suggests that this might not always be the case and that a fundamental reassessment of the clinical significance of HDL-C is warranted. METHOD: This review article is based on a selective literature review. RESULTS: In individuals without a history of cardiovascular events, low concentrations of HDL-C are inversely associated with the risk of future cardiovascular events. This relationship may, however, not apply to patients with metabolic disorders or manifest cardiovascular disease. The classical function of HDL is to mobilise cholesterol from extrahepatic tissues for delivery to the liver for excretion. These roles in cholesterol metabolism as well as many other biological functions of HDL particles are dependent on the number as well as protein and lipid composition of HDL particles. They are poorly reflected by the HDL-C concentration. HDL can even exert negative vascular effects, if its composition is pathologically altered. High serum HDL-C is therefore no longer regarded protective. In line with this, recent pharmacological approaches to raise HDL-C concentration have not been able to show reductions of cardiovascular outcomes. CONCLUSION: In contrast to LDL cholesterol (LDL-C), HDL-C correlates with cardiovascular risk only in healthy individuals. The calculation of the ratio of LDL-C to HDL-C is not useful for all patients. Low HDL-C should prompt examination of additional metabolic and inflammatory pathologies. An increase in HDL-C through lifestyle change (smoking cessation, physical exercise) has positive effects and is recommended. However, HDL-C is currently not a valid target for drug therapy. Springer Berlin Heidelberg 2017-03-24 2017 /pmc/articles/PMC5565659/ /pubmed/28342064 http://dx.doi.org/10.1007/s00392-017-1106-1 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
März, Winfried
Kleber, Marcus E.
Scharnagl, Hubert
Speer, Timotheus
Zewinger, Stephen
Ritsch, Andreas
Parhofer, Klaus G.
von Eckardstein, Arnold
Landmesser, Ulf
Laufs, Ulrich
HDL cholesterol: reappraisal of its clinical relevance
title HDL cholesterol: reappraisal of its clinical relevance
title_full HDL cholesterol: reappraisal of its clinical relevance
title_fullStr HDL cholesterol: reappraisal of its clinical relevance
title_full_unstemmed HDL cholesterol: reappraisal of its clinical relevance
title_short HDL cholesterol: reappraisal of its clinical relevance
title_sort hdl cholesterol: reappraisal of its clinical relevance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565659/
https://www.ncbi.nlm.nih.gov/pubmed/28342064
http://dx.doi.org/10.1007/s00392-017-1106-1
work_keys_str_mv AT marzwinfried hdlcholesterolreappraisalofitsclinicalrelevance
AT klebermarcuse hdlcholesterolreappraisalofitsclinicalrelevance
AT scharnaglhubert hdlcholesterolreappraisalofitsclinicalrelevance
AT speertimotheus hdlcholesterolreappraisalofitsclinicalrelevance
AT zewingerstephen hdlcholesterolreappraisalofitsclinicalrelevance
AT ritschandreas hdlcholesterolreappraisalofitsclinicalrelevance
AT parhoferklausg hdlcholesterolreappraisalofitsclinicalrelevance
AT voneckardsteinarnold hdlcholesterolreappraisalofitsclinicalrelevance
AT landmesserulf hdlcholesterolreappraisalofitsclinicalrelevance
AT laufsulrich hdlcholesterolreappraisalofitsclinicalrelevance